{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fasting+state&page=10",
    "query": {
      "intervention": "Fasting state",
      "page": 10
    },
    "page_size": 10
  },
  "pagination": {
    "page": 10,
    "page_size": 10,
    "total_count": 387,
    "total_pages": 39,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fasting+state&page=11&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Fasting+state&page=9&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T19:15:44.577Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01837719",
      "title": "Bioequivalence Study of Individual Atazanavir and Cobicistat Compared With Atazanavir in Fixed-dose Combination With Cobicistat",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Human Immunodeficiency Virus Type 1 (HIV-1)"
      ],
      "interventions": [
        {
          "name": "Atazanavir",
          "type": "DRUG"
        },
        {
          "name": "Cobicistat",
          "type": "DRUG"
        },
        {
          "name": "Atazanavir/Cobicistat FDC",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Bristol-Myers Squibb",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "49 Years",
        "sex": "ALL",
        "summary": "18 Years to 49 Years"
      },
      "enrollment_count": 64,
      "start_date": "2013-04",
      "completion_date": "2013-06",
      "has_results": true,
      "last_update_posted_date": "2014-08-29",
      "last_synced_at": "2026-10-21T19:15:44.577Z",
      "location_count": 1,
      "location_summary": "Austin, Texas",
      "locations": [
        {
          "city": "Austin",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01837719"
    },
    {
      "nct_id": "NCT05363215",
      "title": "A Study to Assess S-217622 in Participants With Renal Impairment and Healthy Participants",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Renal Impairment"
      ],
      "interventions": [
        {
          "name": "S-217622",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Shionogi",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "80 Years",
        "sex": "ALL",
        "summary": "18 Years to 80 Years"
      },
      "enrollment_count": 32,
      "start_date": "2022-08-10",
      "completion_date": "2023-04-12",
      "has_results": false,
      "last_update_posted_date": "2023-04-24",
      "last_synced_at": "2026-10-21T19:15:44.577Z",
      "location_count": 4,
      "location_summary": "Miami, Florida • Orlando, Florida • Saint Paul, Minnesota",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Saint Paul",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05363215"
    },
    {
      "nct_id": "NCT07465731",
      "title": "A Trial to Compare the Amount of Centanafadine That Enters the Bloodstream for Two Different Formulations of Centanafadine",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy Volunteers"
      ],
      "interventions": [
        {
          "name": "Centanafadine SR",
          "type": "DRUG"
        },
        {
          "name": "Centanafadine QD XR",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Otsuka Pharmaceutical Development & Commercialization, Inc.",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "55 Years",
        "sex": "ALL",
        "summary": "18 Years to 55 Years"
      },
      "enrollment_count": 62,
      "start_date": "2022-10-27",
      "completion_date": "2023-03-26",
      "has_results": false,
      "last_update_posted_date": "2026-03-12",
      "last_synced_at": "2026-10-21T19:15:44.577Z",
      "location_count": 1,
      "location_summary": "Lenexa, Kansas",
      "locations": [
        {
          "city": "Lenexa",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07465731"
    },
    {
      "nct_id": "NCT06348056",
      "title": "A Comparison of the Metabolic Effects of Zinc-Amino Acid (ZnAA) Versus Zinc Gluconate",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Response of Fatty Acid Desaturation to Zinc Intake"
      ],
      "interventions": [
        {
          "name": "30 mg Zn Amino Acid daily for 13 days",
          "type": "DIETARY_SUPPLEMENT"
        },
        {
          "name": "30 mg Zn Gluconate daily for 13 days",
          "type": "DIETARY_SUPPLEMENT"
        }
      ],
      "intervention_types": [
        "DIETARY_SUPPLEMENT"
      ],
      "sponsor": "University of California, Berkeley",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": "50 Years",
        "sex": "MALE",
        "summary": "18 Years to 50 Years · Male only"
      },
      "enrollment_count": 26,
      "start_date": "2024-01-22",
      "completion_date": "2024-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-09-23",
      "last_synced_at": "2026-10-21T19:15:44.577Z",
      "location_count": 1,
      "location_summary": "Berkeley, California",
      "locations": [
        {
          "city": "Berkeley",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06348056"
    },
    {
      "nct_id": "NCT00805129",
      "title": "Everolimus (RAD001) in Metastatic Transitional Cell Carcinoma of the Urothelium",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Bladder Cancer",
        "Metastatic Transitional Cell Carcinoma"
      ],
      "interventions": [
        {
          "name": "Everolimus",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Memorial Sloan Kettering Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 46,
      "start_date": "2008-12-05",
      "completion_date": "2021-12-15",
      "has_results": true,
      "last_update_posted_date": "2022-11-25",
      "last_synced_at": "2026-10-21T19:15:44.577Z",
      "location_count": 1,
      "location_summary": "New York, New York",
      "locations": [
        {
          "city": "New York",
          "state": "New York"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00805129"
    },
    {
      "nct_id": "NCT04243759",
      "title": "Inhibitory Control Smartphone App",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Drinking, Alcohol",
        "Drinking Behavior"
      ],
      "interventions": [
        {
          "name": "Control App Version",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Standard App Version",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Experimental, Feedback App Version",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "University of Florida",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "25 Years",
        "sex": "ALL",
        "summary": "21 Years to 25 Years"
      },
      "enrollment_count": 53,
      "start_date": "2020-11-09",
      "completion_date": "2024-05-31",
      "has_results": true,
      "last_update_posted_date": "2025-05-30",
      "last_synced_at": "2026-10-21T19:15:44.577Z",
      "location_count": 1,
      "location_summary": "Gainesville, Florida",
      "locations": [
        {
          "city": "Gainesville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04243759"
    },
    {
      "nct_id": "NCT04573582",
      "title": "Pharmacokinetics of Enasidenib (CC-90007) in Participants With Mild, Moderate and Severe Hepatic Impairment",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Hepatic Impairment"
      ],
      "interventions": [
        {
          "name": "Enasidenib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Celgene",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "40 Years",
        "maximum_age": "75 Years",
        "sex": "ALL",
        "summary": "40 Years to 75 Years"
      },
      "enrollment_count": 40,
      "start_date": "2020-11-13",
      "completion_date": "2023-03-08",
      "has_results": false,
      "last_update_posted_date": "2024-07-15",
      "last_synced_at": "2026-10-21T19:15:44.577Z",
      "location_count": 3,
      "location_summary": "Miami, Florida • Orlando, Florida • Knoxville, Tennessee",
      "locations": [
        {
          "city": "Miami",
          "state": "Florida"
        },
        {
          "city": "Orlando",
          "state": "Florida"
        },
        {
          "city": "Knoxville",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04573582"
    },
    {
      "nct_id": "NCT02299505",
      "title": "Pharmacokinetic and Safety Study of Lower Doses of Ceritinib Taken With a Low-fat Meal Versus 750 mg of Ceritinib in the Fasted State in Adult Patients With (ALK-positive) Metastatic Non-small Cell Lung Cancer (NSCLC)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Non-Small Cell Lung Cancer"
      ],
      "interventions": [
        {
          "name": "ceritinib",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Novartis Pharmaceuticals",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 306,
      "start_date": "2015-04-09",
      "completion_date": "2020-03-06",
      "has_results": false,
      "last_update_posted_date": "2022-02-09",
      "last_synced_at": "2026-10-21T19:15:44.577Z",
      "location_count": 7,
      "location_summary": "Fayetteville, Arkansas • Loma Linda, California • Indianapolis, Indiana + 4 more",
      "locations": [
        {
          "city": "Fayetteville",
          "state": "Arkansas"
        },
        {
          "city": "Loma Linda",
          "state": "California"
        },
        {
          "city": "Indianapolis",
          "state": "Indiana"
        },
        {
          "city": "Rockville",
          "state": "Maryland"
        },
        {
          "city": "Belleville",
          "state": "New Jersey"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02299505"
    },
    {
      "nct_id": "NCT01244100",
      "title": "Food-Effect Pharmacokinetic Study of PL2200",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Healthy"
      ],
      "interventions": [
        {
          "name": "PL2200 fasted",
          "type": "DRUG"
        },
        {
          "name": "PL2200 fed",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "PLx Pharma",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "21 Years",
        "maximum_age": "65 Years",
        "sex": "ALL",
        "summary": "21 Years to 65 Years"
      },
      "enrollment_count": 20,
      "start_date": "2010-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2010-12-13",
      "last_synced_at": "2026-10-21T19:15:44.577Z",
      "location_count": 1,
      "location_summary": "Houston, Texas",
      "locations": [
        {
          "city": "Houston",
          "state": "Texas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01244100"
    },
    {
      "nct_id": "NCT01149629",
      "title": "Study of the Fed-Fast Pharmocokinetics and Bioequivalance of 300mg Capsules of Droxidopa",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Symptomatic Neurogenic Orthostatic Hypotension"
      ],
      "interventions": [
        {
          "name": "Droxidopa",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Chelsea Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "65 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "65 Years and older"
      },
      "enrollment_count": 24,
      "start_date": "2010-07",
      "completion_date": "2010-08",
      "has_results": false,
      "last_update_posted_date": "2013-03-20",
      "last_synced_at": "2026-10-21T19:15:44.577Z",
      "location_count": 1,
      "location_summary": "Fargo, North Dakota",
      "locations": [
        {
          "city": "Fargo",
          "state": "North Dakota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01149629"
    }
  ]
}